Eisasi Launches Legembi in India for Early Alzheimers Treatment

On 4 August 2026, Eisai introduced approval from the Central Drugs Standard Control Organization. Eisai launched Leqembi, a disease-modifying therapy for early-stage Alzheimer's disease. The medication is meant for those with Alzheimer's disease related to moderate cognitive impairment or mild dementia, and it is intended to treat the underlying disease process rather than just symptoms. Leqembi targets the brain's amyloid beta plaques, which are linked to Alzheimer's disease. Before patients can start therapy, biomarker testing is necessary to confirm amyloid pathology. The treatment is given intravenously. The AIIMS USG Longitudinal Aging Study in India estimated that 8.8 million adults aged 60 and older were living with dementia at the time of launch.

Alzheimer's disease is intended to treat the fundamental cause of the illness rather than just its symptoms. Leqembi targets the brain's amyloid beta plaques, which are linked to Alzheimer's disease. Before patients can start therapy, biomarker testing is necessary to confirm amyloid pathology. The treatment is given intravenously. The debut coincides with India's increasing dementia burden; according to the AIIMS-USC Longitudinal Aging Study, 8.8 million Indians aged 60 and older were estimated to have dementia in 2023.

The maximum retail price of the treatment is Rs 21682 per vial; however, the total cost will vary based on the patient's body weight and necessary dosage. The crucial Phase III trial that supported the drug approval, which included over 800 participants worldwide, did not include Indian patients, according to Eisai. The company will carry out Phase IV post-marketing research to gather more safety and efficacy data from Indian patients as part of the Indian approval procedure. Additionally, the launch coincides with Eli Lilly's introduction of donanemab in India, which increased competition in the nation's developing market for disease-modifying Alzheimer's treatments.

Impact on the Healthcare Industry

By increasing the number of therapy options available to individuals in the early stages of the disease, Lequmbi's introduction could be a significant breakthrough for India's Alzheimer's care environment. Disease-modifying therapies aim to affect the underlying molecular processes linked to Alzheimer's, in contrast to conventional medications that mainly address symptoms. This may promote a stronger emphasis on early disease detection and patient evaluation prior to substantial cognitive impairment. However, patients need a proper diagnosis, biomarker confirmation, and infusion-based treatment facilities, so access to the therapy will depend on more than just the drug.

Demand for specialized neurological care and related healthcare infrastructure may rise because of the launch. It may be necessary for hospitals and neurological facilities to improve their capabilities for brain imaging, biomarker testing, cognitive evaluation, infusion administration, and continuous patient monitoring. To find qualified candidates and oversee patients undergoing disease-modifying treatments, medical personnel could also need more training. Regular cooperation between neurologists, imaging facilities, diagnostic labs, and infusion care providers.

Ligambi's accessibility may also help raise awareness of Alzheimer's and the significance of early detection. Although there is a sizable prospective patient pool in India due to its huge and aging population, delayed diagnosis is still a problem. Demand diagnostic approaches that can identify patients at an earlier stage and evaluate whether they are suitable candidates for therapy may rise as newer medicines become accessible. A more customized and biomarker-driven approach to Alzheimer's care may eventually result from this.

Impact on the Alzheimer's Disease Diagnostics Market

The global Alzheimer's disease diagnostics market size accounted for USD 9.40 billion in 2025 and is predicted to increase from USD 10.42 billion in 2026 to approximately USD 26.21 billion by 2035, expanding at a CAGR of 10.80% from 2026 to 2035.

According to Precedence Research, the market for Alzheimer's disease diagnostics is being bolstered by the aging population's rising desire for early detection and the relation of blood-based biomarkers. Brain imaging, cerebrospinal fluid testing, biomarker assays, genetic testing, and new digital evaluation technologies are all part of the market, while the biomarker testing category is anticipated to increase rapidly over the projection period, and the early-stage diagnosis segment held a 40% share in 2025.

The patients must undergo biomarker testing to prove amyloid pathology before receiving the medication. The introduction of Leqembi is closely related to this market. The need for diagnostic services that can find qualified patients early on may rise due to this necessity. The availability of disease-modifying treatments is making diagnosis a crucial first step toward therapy, strengthening the connection between the development of neurological drugs and sophisticated diagnostic testing.

Therefore, technologies that allow for earlier and more accurate Alzheimer's detection may be of more relevance in India. While PET imaging and other established techniques will continue to support clinical evaluation, blood-based biomarker testing may become especially relevant since it may provide a less intrusive alternative to some classic diagnostic approaches. According to Precedence Research, it identifies biomarker testing as one of the fastest-growing areas of the Alzheimer's diagnostics market, reflecting the increasing emphasis on identifying disease-related biological changes before symptoms become more severe.

India's healthcare system may need to increase access to these diagnostic tools in addition to infusion facilities as legembi use grows. Increased testing of accessibility may assist doctors in determining treatment eligibility, identifying suitable candidates, and tracking the course of illness. Diagnostics may become a more crucial part of the nation's developing ecosystem for treating Alzheimer's disease. 

Impact on the CNS Drug Discovery Market

The global CNS drug discovery market size was calculated at USD 9.80 billion in 2025 and is predicted to increase from USD 10.86 billion in 2026 to approximately USD 27.55 billion by 2035, expanding at a CAGR of 10.90% from 2026 to 2035.

According to Precedence Research, Alzheimer's disease accounted for 24% of the CNS drug discovery market in 2025, making it the larger indication. Over the course of the forecast period, it is anticipated to increase at the fastest CAGR of 13.5%. Investment in CNS drug development is supported by the rising incidence of neurological illness and the unfulfillments and developments in biomarker-based research.

This market is strongly associated with Eisai's launch of Legembi in India, which signifies the commercialization of a disease-modifying strategy for Alzheimer's. The treatment emphasis on amyloid beta pathology is indicative of a larger trend in CNS drug development toward treatments that target certain biological pathways as opposed to merely managing symptoms. Therefore, the launch in India may help raise awareness of and encourage the use of disease-modifying techniques in the nation's neurological treatment system.

Pharmaceutical companies may be encouraged to invest more in Alzheimer's research and the creation of next-generation CNS medicines as these therapies become more widely available. According to Precedence Research, due to the aging population and substantial unmet medical need, Alzheimer's is predicted to continue to be one of the fastest-growing areas of CNC drug discovery. Researchers may be better able to find suitable subjects and assess possible treatments throughout clinical development thanks to developments in biomarkers and patient selection.

There may be more competition in India's developing market for Alzheimer's disease-modifying therapies. Pharmaceutical companies may compete on treatment efficacy, patient access, administration techniques, and cost support programs as Leqembi enters the market soon after Eli Lilly's donanemab. However, due to issues with delayed diagnosis, limited capacity for biomarker testing, infusion requirements, and a lack of comprehensive payment coverage, adoption is anticipated to expand gradually.

About Eisai

A Japanese pharmaceutical business called Eisai is dedicated to finding and creating medications for conditions including cancer and neurology. As a disease-modifying treatment for early Alzheimer's disease, the business created lecanemab, which is sold under the brand name Leqembi. More than 50 nations and regions, including the US, Japan, Europe, and China, have approved the treatment.

The company's foothold in a burgeoning market for Alzheimer's therapy, where the number of individuals suffering from dementia is rising, is increased by the Indian launch. Early patient identification has been positioned by Eisai as a crucial component of Leqembi treatment. To address some of the access and awareness issues related to more recent Alzheimer's treatments, the business is now offering support programs designed to assist qualified patients in starting and maintaining therapy.

Eisai will carry out Phase IV post-marketing research to gather more safety and efficacy data from Indian patients as required by Indian regulations. As the therapy use grows throughout the nations, this may offer locally pertinent clinical evidence. With other disease-modifying Alzheimer's treatments hitting the Indian market, the company's launch also puts it in a growing competitive climate.

With the release of Leqembi, Alzheimer's treatment has shifted more broadly toward treatments that try to slow the disease's progression. Its introduction could spur development in several related fields for India, such as neurological diagnostics, biomarker testing, infusion infrastructure, and specialized treatment. In the era, therapy success in the Indian market will rely not only on regulatory availability but also on patients' capacity to receive an early diagnosis, verify their eligibility for treatment, and have access to the facilities needed for continued therapy.